Treatment of Metastatic Pancreatic Cancer with NTRK Fusion

In a subset of patients with metastatic pancreatic cancer, tumour molecular profiling identifies an NTRK gene fusion — a specific genomic alteration that defines a distinct, actionable sub-population with a dedicated treatment pathway.

Clinical scenario

Metastatic pancreatic cancer in a patient whose tumour harbours an NTRK fusion. Identification of this fusion through molecular testing is the key factor that shapes the therapeutic approach in this setting.

Treatment approach (partial overview)

When an NTRK fusion is confirmed, a targeted inhibitor therapy directed specifically at the TRK pathway is recommended — distinct from the conventional chemotherapy regimens used in unselected metastatic pancreatic cancer.

The complete evidence-based regimen, agent selection, and full guidance are available via the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2023.08.009

In patients with an NTRK fusion, larotrectinib or entrectinib is recommended [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C].

View source ↗